z-logo
open-access-imgOpen Access
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
Author(s) -
Michelle A. Rudek,
Roisín M. Connolly,
Janelle M. Hoskins,
Elizabeth GarrettMayer,
Stacie C. Jeter,
Deborah K. Armstrong,
John H. Fetting,
Vered Stearns,
Laurie A. Wright,
Ming Zhao,
Stanley P. Watkins,
Howard L. McLeod,
Nancy E. Davidson,
Antonio C. Wolff
Publication year - 2013
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/7ceh-c266
Subject(s) - capecitabine , pharmacogenetics , metastatic breast cancer , medicine , pharmacokinetics , breast cancer , oncology , pharmacology , cancer , colorectal cancer , genotype , chemistry , biochemistry , gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom